BNET Industries
MannKind Corp. (MNKD) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $10.0K
- Profit
- Dec 31 2007
- ($293.1M)
- Market Cap
- Aug 27 2008
- $319.0M
Latest News and Analysis
MannKind Corp. Q1 2008 Earnings Call Transcript
MannKind Corp. Q1 2008 Earnings Call Transcript
MannKind Corporation Q4 2007 Earnings Call Transcript
MannKind Corporation Q4 2007 Earnings Call Transcript
Additional Resources
MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
VALENCIA, Calif., Aug. 4 /PRNewswire-FirstCall/ -- MannKind Corporation will release its 2008 second quarter financial results on Monday, August 11, 2008 at 4:00 p.m. EDT. Management of the Company will host a conference call to discuss the second quarter financial results, clinical progress and other Company...
BeaconEquity.com Issues Technical Trade Alerts on Market Movers: EXXI, IVAN, AXAS, MNKD, CYTK, SIRI
DALLAS, July 31 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://beaconequity.com/m Today's Trade Alerts include: Energy XXI Ltd. , Ivanhoe Energy Inc. , Abraxas Petroleum...
MannKind to Present at Upcoming Conferences
VALENCIA, Calif., June 16 /PRNewswire-FirstCall/ -- MannKind Corporation , focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences. -- 18th Annual Wachovia Nantucket Equity Conference on Monday, June 23, ...
IMI Intelligent Medical Implants AG Announces the Appointment of Dr. Stephen J. McCormack as Chief Executive Officer
ZUG, Switzerland -- IMI Intelligent Medical Implants AG ("IMI") (www.intmedimplants.com), announced today that it has appointed Dr. Stephen J. McCormack as CEO. He was previously Chairman of the Board of Directors and will remain as a board member. Tim Haines, a member of IMI's Board...
MannKind to Present at Upcoming Conferences
VALENCIA, Calif., May 7 /PRNewswire-FirstCall/ -- MannKind Corporation , focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences. -- Bank of America Health Care Conference on Wednesday, May 14, 2008 at 8:40...
Zacks Analyst Blog Highlights: EnCana, MannKind, Pfizer, Eli Lilly and Novo Nordisk
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: EnCana (NYSE: ECA), MannKind (Nasdaq: MNKD), Pfizer (NYSE: PFE), Eli Lilly...
Zacks Analyst Blog Highlights: MannKind Corporation, Pfizer, Eli Lilly, Novo-Nordisk and LM Ericsson
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: MannKind Corporation (Nasdaq: MNKD), Pfizer (NYSE: PFE), Eli Lilly (NYSE: LLY),...
BellwetherReport.com Free Analyst Review for NKTR, MNKD, EPMD and AMGI
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased research on the companiesmentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have scheduled interviews with a number of the...
JKA, ASMI, ESGR, MNKD, TDSC, CBF Have Been Added To Naked Short List Today.
M2 PRESSWIRE-19 March 2008-BUYINS.NET: JKA, ASMI, ESGR, MNKD, TDSC, CBF Have Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:19032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE...
MannKind to Present at the Cowen and Company Healthcare Conference
VALENCIA, Calif., March 13 /PRNewswire-FirstCall/ -- MannKind Corporation , focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Cowen and Company Healthcare Conference on March 17, 2008 at 3:15 PM ET at the Marriott Copley Place Hotel in Boston,...
MannKind Corporation Response to Recent Market Events
VALENCIA, Calif., March 10 /PRNewswire-FirstCall/ -- MannKind Corporation today issued the following statement in response to recent market events: MannKind is absolutely committed to the continued development of its lead development product, TechnosphereR Insulin. We use our small, patient-friendly MedtoneR inhaler to deliver TechnosphereR Insulin to...
MannKind Corporation Reports Fourth Quarter and Year end Results.
M2 PRESSWIRE-5 March 2008-investorIM: MannKind Corporation Reports Fourth Quarter and Year end ResultsC1994-2008 M2 COMMUNICATIONS LTD RDATE:05032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do...
MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
- Conference Call to Begin Today at 9:00 a.m. ET - VALENCIA, Calif., March 4 /PRNewswire-FirstCall/ -- MannKind Corporation today reported financial results for the fourth quarter and year ended December 31, 2007. For the fourth quarter of 2007, total operating expenses were $79.1...
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
VALENCIA, Calif., Feb. 28 /PRNewswire-FirstCall/ -- MannKind Corporation will release its 2007 fourth quarter financial results on Tuesday, March 4, 2008 at 7:00 a.m. ET. Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company...
Wall Street News Alert: Investment Alert: ELHI! February 20, 2008
Wall Street News Alert's "stocks to watch" thismorning are: Edgeline Holdings, Inc. (OTCBB: ELHI), MannKind Corporation(NASDAQ: MNKD), Holly Corporation (NYSE: HOC) and Schering-PloughCorporation (NYSE: SGP). Having just announced one of its research programs for which it has rightswas awarded a peer reviewed National Institute Of Health Grant for$179,000, Edgeline Holdings,...
The Mannkind Corp Product Pipeline Report Delivers the Latest and the Most Comprehensive Intelligence Available On Mannkind Corps Current Pipeline Portfolio.
M2 PRESSWIRE-4 January 2008-Research and Markets: The Mannkind Corp Product Pipeline Report Delivers the Latest and the Most Comprehensive Intelligence Available On Mannkind Corps Current Pipeline PortfolioC1994-2008 M2 COMMUNICATIONS LTD RDATE:07012008 Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c78530) has...
Zacks Bull and Bear of the Day Highlights: Verisign, MannKind, Ford and Lamar Advertising
CHICAGO -- Zacks Equity Research highlights Verisign, Inc. (Nasdaq: VRSN) as the Bull of the Day and MannKind Corp. (Nasdaq: MNKD) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Ford (NYSE: F) and Lamar Advertising Company (Nasdaq: LAMR). Full analysis of...
Research and Markets: The MannKind Corp Product Pipeline Report Delivers the Latest and the Most Comprehensive Intelligence Available on MannKind Corps Current Pipeline Portfolio
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c78527) has announced the addition of MannKind Corp - Product Pipeline Report to their offering. The MannKind Corp Latest Product Pipeline Report contains contact information, business summary, company details, selected financial data, detailed product pipeline (including disease hub, description,...
- Next »
- page 1 of 1
- « Previous
Sort byClose
- Incorporated: 1991
- CEO: Mr. Alfred E. Mann
- Employees: 609
MannKind is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. As of Dec 31 2006, Co.'s lead investigational product candidate is the Technosphere Insulin System, a dry powder therapy consisting of its proprietary Technosphere particles onto which insulin molecules are loaded. Co.'s Technosphere formulation technology is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. These loaded particles are then aerosolized and inhaled into the deep lung using Co.'s proprietary MedTone inhaler.
Key Competitors
MannKind Corp. Company Info
Board of Directors
Mr. Alfred E. Mann
Chairman
Mr. Abraham E. Cohen
Mr. Hakan S. Edstrom
Ms. Heather Hay Murren
Mr. Ronald Consiglio
Dr. Michael A. Friedman M.D.
Mr. Kent Kresa
Mr. David H. MacCallum
Mr. Henry L. Nordhoff
Contact Information
28903 North Ave Paine
Valencia, CA
661 775-5300